These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8631036)

  • 41. Immunotoxins: status and prospects.
    Spooner RA; Lord JM
    Trends Biotechnol; 1990 Jul; 8(7):189-93. PubMed ID: 1366624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotoxins: a clinical review of their use in the treatment of malignancies.
    Hertler AA; Frankel AE
    J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
    Filpula D; Yang K; Basu A; Hassan R; Xiang L; Zhang Z; Wang M; Wang QC; Ho M; Beers R; Zhao H; Peng P; Zhou J; Li X; Petti G; Janjua A; Liu J; Wu D; Yu D; Zhang Z; Longley C; FitzGerald D; Kreitman RJ; Pastan I
    Bioconjug Chem; 2007; 18(3):773-84. PubMed ID: 17346030
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotoxin therapy: prospects for the future.
    Corliss J
    J Natl Cancer Inst; 1989 Dec; 81(24):1862-3. PubMed ID: 2593161
    [No Abstract]   [Full Text] [Related]  

  • 46. Therapeutic potential of anticancer immunotoxins.
    Choudhary S; Mathew M; Verma RS
    Drug Discov Today; 2011 Jun; 16(11-12):495-503. PubMed ID: 21511052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.
    Keppler-Hafkemeyer A; Kreitman RJ; Pastan I
    Int J Cancer; 2000 Jul; 87(1):86-94. PubMed ID: 10861457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].
    Chiron MF
    Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interferon: anticancer agent having multifarious activity.
    Yabrov AA
    Prog Clin Cancer; 1982; 8():99-145. PubMed ID: 6185970
    [No Abstract]   [Full Text] [Related]  

  • 50. Immunotoxin therapy for hematologic malignancies: where are we heading?
    Madhumathi J; Devilakshmi S; Sridevi S; Verma RS
    Drug Discov Today; 2016 Feb; 21(2):325-32. PubMed ID: 26049016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel genetic immunotoxins and intracellular antibodies for cancer therapy.
    Chen SY; Marasco WA
    Semin Oncol; 1996 Feb; 23(1):148-53. PubMed ID: 8607024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotoxin: A new tool for cancer therapy.
    Allahyari H; Heidari S; Ghamgosha M; Saffarian P; Amani J
    Tumour Biol; 2017 Feb; 39(2):1010428317692226. PubMed ID: 28218037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted antibodies in the treatment of lymphomas.
    Falini B; Terenzi A; Liso A; Flenghi L; Solinas A; Pasqualucci L
    Cancer Surv; 1997; 30():295-309. PubMed ID: 9547998
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical assessments of 90Y-labeled C110 anti-carcinoembryonic antigen immunotoxin: a therapeutic immunoconjugate for human colon cancer.
    Ito T; Qiu H; Collins JA; Brill AB; Johnson DK; Griffin TW
    Cancer Res; 1991 Jan; 51(1):255-60. PubMed ID: 1988087
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
    Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
    J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurotoxicity of immunotoxins.
    Ilercil O; Laske DW; Walbridge S; Muaszko K; Oldfield EH; Youle RJ
    Mol Chem Neuropathol; 1994; 21(2-3):379-86. PubMed ID: 8086044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monoclonal antibodies and immunoconjugates for cancer treatment.
    Baldwin RW; Byers VS; Pimm MV
    Cancer Chemother Biol Response Modif; 1988; 10():397-415. PubMed ID: 3079393
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy of intrathecal immunotoxin therapy in an animal model of leptomeningeal neoplasia.
    Zovickian J; Youle RJ
    J Neurosurg; 1988 May; 68(5):767-74. PubMed ID: 3258632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vascular targeting--a new approach to the therapy of solid tumors.
    Burrows FJ; Thorpe PE
    Pharmacol Ther; 1994 Oct; 64(1):155-74. PubMed ID: 7846113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
    Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
    Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.